ZSCAN22

Across TCGA pan-cancer cohorts, ZSCAN22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZSCAN22 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ZSCAN22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZSCAN22 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

SKCM, STAD, and PRAD are the cancer types where ZSCAN22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.530	0.880	.001	12	view →
STAD	DFS	Median	All	1.000	0.379	.029	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZSCAN22–SKCM (OS)

Open the SKCM breakdown →